Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group

Annals of Oncology

Volumn 13, Issue SUPPL. 1, 2002, Pages 84-85

  Wiedenmann, S ^a   Schiller, P ^a   Paulus, U ^a   Wolf, J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; HODGKIN DISEASE; HUMAN; INFRARED RADIATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDIASTINUM MASS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RISK FACTOR; DISEASE COURSE; GERMANY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GERMANY; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 0036258313     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/13.S1.84     Document Type: Article

References (3)

1. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood
2. Second interim analysis of the HD7 trial of the GHSG: 2 cycles ABVD plus extende field radiotherapy is more effective than radiotherapy alone in early stage HD [4411]
3. For intermediate stage Hodgkin's disease extended field radiation after effective chemotherapy is obsolete: Interim analysis of the HD8 trial (GHSG) [2361]